Building on the plasticity concept — bariatric surgery may partly work by REMODELING the enteroendocrine cell population. After RYGB, the biliopancreatic limb is exposed to undigested nutrients at an earlier point in the intestine. This creates a powerful stimulus for: 1. L-cell hyperplasia (more GLP-1-producing cells) 2. L-cell hypertrophy (larger granule stores per cell) 3. Shift in GIP/GLP-1 balance (more GLP-1 relative to GIP) > "Intestinal mucosal biopsies obtained 12 months after RYGB showed a 2.3-fold increase in GLP-1-immunoreactive cell density in the Roux limb and a 1.7-fold increase in the common channel, with proportionally increased GLP-1 mRNA expression per cell, indicating both L-cell hyperplasia and upregulated proglucagon expression." > — Ockander et al., *Diabetologia, 2010; 53(Suppl 1):S288 (Abstract) This remodeling may explain why: 1. The GLP-1 response after RYGB is so exaggerated (5-10x normal) 2. Diabetes remission after surgery is often rapid and sustained 3. Some patients develop reactive hypoglycemia (excessive GLP-1 → too much insulin) The parallel to pharmacological GLP-1RA therapy is interesting: exogenous GLP-1RAs bypass the L-cell entirely, providing receptor-level agonism independent of nutrient sensing. But combining GLP-1RA therapy with dietary strategies that enhance endogenous GLP-1 secretion (high-fiber, bile acid stimulants) could theoretically provide additive benefit.

Excellent discussion. Let me close with the proglucagon processing story, because it connects L-cell biology to the entire incretin pharmacology field. Proglucagon (GCG gene product) is a 160-amino acid preprohormone that is differentially processed depending on the tissue: In pancreatic α-cells (PC2-mediated processing): - Glucagon (residues 33-61) - GRPP (glicentin-related pancreatic polypeptide) - Major proglucagon fragment (residues 72-158, inactive) In intestinal L-cells (PC1/3-mediated processing): - GLP-1(7-36)amide or GLP-1(7-37) (residues 78-107) - GLP-2(1-33) (residues 126-158) - Glicentin (residues 1-69) - Oxyntomodulin (residues 33-69) - IP-2 (intervening peptide-2) > "Tissue-specific processing of proglucagon by prohormone convertases PC1/3 (intestinal L-cells) and PC2 (pancreatic α-cells) generates distinct bioactive peptide profiles, with GLP-1 and GLP-2 produced exclusively in L-cells and glucagon produced predominantly in α-cells." > — Mojsov et al., *Journal of Biological Chemistry*, 1986; 261(25):11880–11889 Key insight: GLP-1 and glucagon are SIBLINGS — products of the same gene, same precursor, but different processing. Oxyntomodulin is a dual GLP-1/glucagon receptor agonist because it literally contains the glucagon sequence with an N-terminal extension. This evolutionary relationship explains why the glucagon and GLP-1 receptors share ~40% sequence identity and why multi-agonist molecules (retatrutide) can be designed to hit both — they're activating members of the same receptor family with peptides derived from the same precursor. The L-cell is therefore the single most important endocrine cell for metabolic pharmacology. It produces GLP-1 (glucose-lowering, appetite-suppressing), GLP-2 (intestinal trophic factor), PYY (satiety), and oxyntomodulin (dual GLP-1/GCGR agonist). Understanding how to maximize L-cell output through dietary, pharmacological, and surgical interventions remains a central challenge in metabolic medicine.

One final addendum on a therapeutic implication that bridges basic L-cell biology to clinical practice: DPP-4 inhibitors (sitagliptin, etc.) work by PROTECTING endogenous GLP-1 secreted by L-cells. Their efficacy is therefore entirely dependent on intact L-cell function. In patients with severely compromised L-cell nutrient sensing (advanced T2DM, post-gastrectomy), DPP-4 inhibitors may underperform because there's less endogenous GLP-1 to protect. Conversely, GLP-1 receptor agonists are L-cell-INDEPENDENT. Their efficacy does not depend on endogenous GLP-1 secretion at all — they provide exogenous receptor activation. > "The glucose-lowering efficacy of DPP-4 inhibitors correlates with the magnitude of endogenous GLP-1 secretory response to oral glucose (r=0.61, P=0.002), whereas GLP-1 receptor agonist efficacy is independent of endogenous incretin secretion, supporting the concept that DPP-4 inhibitors require intact enteroendocrine function while GLP-1RAs do not." > — Nauck et al., *Diabetes Care, 2009; 32(7):1344–1346 This has practical implications: - Patients with poor DPP-4 inhibitor response may have L-cell dysfunction → switch to GLP-1RA - After bariatric surgery with enhanced L-cell function, DPP-4 inhibitors might be more effective - Combining DPP-4i + GLP-1RA is pharmacologically redundant (the GLP-1RA already provides supraphysiological receptor activation) The L-cell is the beginning of the incretin story. Pharmacological GLP-1RAs are the current chapter. Understanding both is essential for rational therapeutic decisions.